[
  {
    "id": "854fb500-96f7-4ef2-b61a-d14ed35af74f",
    "moduleType": "general",
    "clinicalScenario": "Breast Cancer",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:27.907Z",
    "updatedAt": "2025-06-28T17:06:27.907Z"
  },
  {
    "id": "9fbb1864-e296-4054-988e-bea1379d94a0",
    "moduleType": "general",
    "clinicalScenario": "Systemic Adjuvant Treatment",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "HR-Positive – HER2-Positive Disease (BINV-5)",
      "HR-Positive – HER2-Negative Disease:",
      "HR-Negative – HER2-Positive Disease (BINV-9)",
      "HR-Negative – HER2-Negative Disease (BINV-10)",
      "Favorable Histologies (BINV-11)"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:28.036Z",
    "updatedAt": "2025-06-28T17:06:28.036Z"
  },
  {
    "id": "ed37682f-3359-499d-8c3a-94f5cad7925c",
    "moduleType": "general",
    "clinicalScenario": "UPDATES",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "Second line: HER2 IHC 0+ moved to new row and fam-trastuzumab deruxtecan-nxki was changed from a category 1, preferred recommendation to a",
      "Footnote verbiage was updated to align with FDA approved scoring and CAP reporting: The distinction between HER2 test results of IHC 0/absent",
      "Footnote f revised: Fam-trastuzumab deruxtecan-nxki may be used for HER2 IHC 0+ 1+ or 2+/ISH negative, in those previously treated with at least",
      "Second Line, row 3 revised: No germline BRCA1/2 mutation and HER2 IHC 0+, 1+ , or 2+/ISH negative.",
      "Second Line, row 3, column 2: Fam-trastuzumab deruxtecan-nxki changed from a category 1, preferred to a category 2A, other recommended regimen.",
      "Footnote k revised: Fam-trastuzumab deruxtecan may be considered in a later line for HER2 IHC 0+, 1+ or 2+/ISH negative, if not used in second line"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:28.110Z",
    "updatedAt": "2025-06-28T17:06:28.110Z"
  },
  {
    "id": "2953238c-b0fc-4db0-b23e-be8b0a3a8433",
    "moduleType": "cdu",
    "clinicalScenario": "Systemic therapy selection and administration",
    "inputParameters": {
      "stage": "required",
      "biomarkers": "required",
      "comorbidities": "recommended",
      "performanceStatus": "required"
    },
    "nccnReferences": [
      "BINV-20"
    ],
    "recommendedActions": [
      "Last node, added \"and Supportive Care\".",
      "Regimen revised: AC (doxorubicin/cyclophosphamide) followed or preceded by carboplatin + taxane (paclitaxel or docetaxel).",
      "Added dosing for AC followed or preceded by carboplatin + taxane (paclitaxel).",
      "Erratum: \"Datopotamab deruxtecan-dlnk is indicated as second- or subsequent-line therapy for those who have received a prior endocrine-based",
      "For Breast Cancer Version 1.2025, BINV-M 6 of 10: Dosing correction for AC followed or preceded by carboplatin + docetaxel.",
      "Regimen clarified: TC followed by or preceded by AC was replaced with AC (doxorubicin/cyclophosphamide) followed or preceded by carboplatin +",
      "Erratum: Paclitaxel + trastuzumab + pertuzumab was inadvertently listed under \"Adjuvant setting only\". This has been corrected and this regimen is",
      "Footnotes were adjusted in the table.",
      "Dosing added for AC followed or preceded by carboplatin + docetaxel.",
      "Formatting change for Docetaxel + Carboplatin + Pembrolizumab.",
      "Dosing correction for Docetaxel + Carboplatin + Pembrolizumab.",
      "Reference 34 added: Sohn J, Kim GM, Jung KH, et al. A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.90",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:28.266Z",
    "updatedAt": "2025-06-28T17:06:28.266Z"
  },
  {
    "id": "0238e03e-aa7e-4723-8fa5-b10e734b4918",
    "moduleType": "general",
    "clinicalScenario": "BINV-20",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "Last node, added \"and Supportive Care\".",
      "Regimen revised: AC (doxorubicin/cyclophosphamide) followed or preceded by carboplatin + taxane (paclitaxel or docetaxel).",
      "Added dosing for AC followed or preceded by carboplatin + taxane (paclitaxel).",
      "Erratum: \"Datopotamab deruxtecan-dlnk is indicated as second- or subsequent-line therapy for those who have received a prior endocrine-based",
      "For Breast Cancer Version 1.2025, BINV-M 6 of 10: Dosing correction for AC followed or preceded by carboplatin + docetaxel.",
      "Regimen clarified: TC followed by or preceded by AC was replaced with AC (doxorubicin/cyclophosphamide) followed or preceded by carboplatin +",
      "Erratum: Paclitaxel + trastuzumab + pertuzumab was inadvertently listed under \"Adjuvant setting only\". This has been corrected and this regimen is",
      "Footnotes were adjusted in the table.",
      "Dosing added for AC followed or preceded by carboplatin + docetaxel.",
      "Formatting change for Docetaxel + Carboplatin + Pembrolizumab.",
      "Dosing correction for Docetaxel + Carboplatin + Pembrolizumab.",
      "Reference 34 added: Sohn J, Kim GM, Jung KH, et al. A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:28.341Z",
    "updatedAt": "2025-06-28T17:06:28.341Z"
  },
  {
    "id": "21dee01e-bcc9-4efa-a953-0f4594e8735f",
    "moduleType": "general",
    "clinicalScenario": "DCIS-1",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "Footnote g revised: Surgical axillary staging should not be performed for preoperative (biopsy-determined) pure DCIS unless there is some clinical-pathologic",
      "Footnote h added: A SLNB may be considered in the setting of 1) mastectomy for DCIS, 2) excision in an anatomic location compromising the performance of",
      "Footnote m, last sentence revised: Select patients with \"low\" risk DCIS may be considered suitable for APBI/PBI or omission of RT (endocrine therapy alone, if"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:28.489Z",
    "updatedAt": "2025-06-28T17:06:28.489Z"
  },
  {
    "id": "3335681b-6745-4f3c-93b7-0a6ffea257cd",
    "moduleType": "general",
    "clinicalScenario": "DCIS-2",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "Surveillance/Follow-up, 2nd bullet revised: First mammogram 6–12 mo, after end of RT, if given, or after BCS therapy (category 2B) if no RT is given",
      "Footnote q revised: The standard dose of tamoxifen is 20 mg/day for 5 years. Low-dose tamoxifen (5 mg/day or 10 mg/every other day, for 3 years) is"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2B",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:28.640Z",
    "updatedAt": "2025-06-28T17:06:28.640Z"
  },
  {
    "id": "796b0686-952a-4aac-be05-662f4c37931d",
    "moduleType": "opd",
    "clinicalScenario": "Initial breast cancer workup and staging",
    "inputParameters": {
      "age": "required",
      "symptoms": "required",
      "familyHistory": "recommended",
      "priorBreastImaging": "recommended"
    },
    "nccnReferences": [
      "BINV-1"
    ],
    "recommendedActions": [
      "Workup",
      "Clinical Stage"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.95",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:28.788Z",
    "updatedAt": "2025-06-28T17:06:28.788Z"
  },
  {
    "id": "4062b643-f941-470f-99f3-0db32cd1c284",
    "moduleType": "cdu",
    "clinicalScenario": "Systemic therapy selection and administration",
    "inputParameters": {
      "stage": "required",
      "biomarkers": "required",
      "comorbidities": "recommended",
      "performanceStatus": "required"
    },
    "nccnReferences": [
      "BINV-2"
    ],
    "recommendedActions": [
      "Column headers added: Surgery, Adjuvant Systemic Therapy, Nodal Status, RT",
      "Column 2",
      "pN1a pathway, bullet 1 revised: cT1–T3 2, cN0",
      "pN1a pathway, \"No\" node, last column revised: Whole breast RT with inclusion of any portion of the undissected axilla at risk ± boost to tumor bed",
      "Footnote o revised: Sentinel node biopsy may be omitted based on the SSO Choosing Wisely recommendation in patients ≥70 years of age with HR+/",
      "Footnote p added: Determined by surgery, clinical findings, or radiographic imaging.",
      "Footnote q added: Based on emerging data from the SOUND trial, patients with HR+/HER2-negative tumors, pT1, N0 (node negative by axillary"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": "0.90",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:28.937Z",
    "updatedAt": "2025-06-28T17:06:28.937Z"
  },
  {
    "id": "9e136bea-b76a-4eea-ab25-36ec5eac5e4d",
    "moduleType": "general",
    "clinicalScenario": "BINV-2",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "Column headers added: Surgery, Adjuvant Systemic Therapy, Nodal Status, RT",
      "Column 2",
      "pN1a pathway, bullet 1 revised: cT1–T3 2, cN0",
      "pN1a pathway, \"No\" node, last column revised: Whole breast RT with inclusion of any portion of the undissected axilla at risk ± boost to tumor bed",
      "Footnote o revised: Sentinel node biopsy may be omitted based on the SSO Choosing Wisely recommendation in patients ≥70 years of age with HR+/",
      "Footnote p added: Determined by surgery, clinical findings, or radiographic imaging.",
      "Footnote q added: Based on emerging data from the SOUND trial, patients with HR+/HER2-negative tumors, pT1, N0 (node negative by axillary"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:29.162Z",
    "updatedAt": "2025-06-28T17:06:29.162Z"
  },
  {
    "id": "f4585feb-37a0-4659-bac7-8f1beaf31dae",
    "moduleType": "general",
    "clinicalScenario": "BINV-17",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "Endocrine therapy"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:31.484Z",
    "updatedAt": "2025-06-28T17:06:31.484Z"
  },
  {
    "id": "08e900f6-4791-482f-93fb-f5009e336c49",
    "moduleType": "cdu",
    "clinicalScenario": "Systemic therapy selection and administration",
    "inputParameters": {
      "stage": "required",
      "biomarkers": "required",
      "comorbidities": "recommended",
      "performanceStatus": "required"
    },
    "nccnReferences": [
      "BINV-5"
    ],
    "recommendedActions": [
      "pT1c-pT3 pathway revised: Adjuvant chemotherapy with trastuzumab (category 1) (± pertuzumab for pT2-T3) and endocrine therapy",
      "Footnote hh revised: The prognosis of benefit of HER2-targeted therapy is uncertain in patients with HER2-positive breast cancer with pT1a–b, N0",
      "Footnote ii revised: Adjuvant chemotherapy with weekly paclitaxel and trastuzumab can be considered for pT1,N0,M0, HER2-positive cancers,"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": "0.90",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:29.461Z",
    "updatedAt": "2025-06-28T17:06:29.461Z"
  },
  {
    "id": "35b4e138-bf58-49c4-9f59-e2c4dad0c71e",
    "moduleType": "inpatient",
    "clinicalScenario": "Treatment monitoring and toxicity management",
    "inputParameters": {
      "vitalSigns": "required",
      "toxicityGrade": "required",
      "currentTreatment": "required"
    },
    "nccnReferences": [
      "BINV-5"
    ],
    "recommendedActions": [
      "pT1c-pT3 pathway revised: Adjuvant chemotherapy with trastuzumab (category 1) (± pertuzumab for pT2-T3) and endocrine therapy",
      "Footnote hh revised: The prognosis of benefit of HER2-targeted therapy is uncertain in patients with HER2-positive breast cancer with pT1a–b, N0",
      "Footnote ii revised: Adjuvant chemotherapy with weekly paclitaxel and trastuzumab can be considered for pT1,N0,M0, HER2-positive cancers,"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": "0.85",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:29.537Z",
    "updatedAt": "2025-06-28T17:06:29.537Z"
  },
  {
    "id": "c2cc4001-964b-4773-b8d6-2a22a3e3e9a1",
    "moduleType": "general",
    "clinicalScenario": "BINV-5",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "pT1c-pT3 pathway revised: Adjuvant chemotherapy with trastuzumab (category 1) (± pertuzumab for pT2-T3) and endocrine therapy",
      "Footnote hh revised: The prognosis of benefit of HER2-targeted therapy is uncertain in patients with HER2-positive breast cancer with pT1a–b, N0",
      "Footnote ii revised: Adjuvant chemotherapy with weekly paclitaxel and trastuzumab can be considered for pT1,N0,M0, HER2-positive cancers,"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:29.771Z",
    "updatedAt": "2025-06-28T17:06:29.771Z"
  },
  {
    "id": "36d882b2-c872-4b7b-990c-48de7f881a94",
    "moduleType": "cdu",
    "clinicalScenario": "Systemic therapy selection and administration",
    "inputParameters": {
      "stage": "required",
      "biomarkers": "required",
      "comorbidities": "recommended",
      "performanceStatus": "required"
    },
    "nccnReferences": [
      "BINV-6"
    ],
    "recommendedActions": [
      "Middle pathway, column 3, new node added: Determine if candidate for chemotherapy (Also for BINV-7)",
      "Footnote removed: Addition of 1 year of adjuvant olaparib is an option for select patients with germline BRCA1/2 mutation after completion of adjuvant"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.90",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:29.918Z",
    "updatedAt": "2025-06-28T17:06:29.918Z"
  },
  {
    "id": "d95627ae-79d0-419a-9370-8f0c73fc97dd",
    "moduleType": "general",
    "clinicalScenario": "BINV-6",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "Middle pathway, column 3, new node added: Determine if candidate for chemotherapy (Also for BINV-7)",
      "Footnote removed: Addition of 1 year of adjuvant olaparib is an option for select patients with germline BRCA1/2 mutation after completion of adjuvant"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:29.993Z",
    "updatedAt": "2025-06-28T17:06:29.993Z"
  },
  {
    "id": "eeb3ac89-96df-4853-bf85-8c11aa1b8734",
    "moduleType": "cdu",
    "clinicalScenario": "Systemic therapy selection and administration",
    "inputParameters": {
      "stage": "required",
      "biomarkers": "required",
      "comorbidities": "recommended",
      "performanceStatus": "required"
    },
    "nccnReferences": [
      "BINV-7"
    ],
    "recommendedActions": [
      "Not a candidate for chemotherapy, last column, new node added: Adjuvant endocrine therapy ± ovarian suppression/ablation. Consider adjuvant"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.90",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:30.141Z",
    "updatedAt": "2025-06-28T17:06:30.141Z"
  },
  {
    "id": "69ae4347-14b4-43d5-ab1d-b2d34e770d17",
    "moduleType": "general",
    "clinicalScenario": "BINV-7",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "Not a candidate for chemotherapy, last column, new node added: Adjuvant endocrine therapy ± ovarian suppression/ablation. Consider adjuvant"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:30.214Z",
    "updatedAt": "2025-06-28T17:06:30.214Z"
  },
  {
    "id": "723695f4-a461-43ed-bdf7-7ad10352e1bd",
    "moduleType": "cdu",
    "clinicalScenario": "Systemic therapy selection and administration",
    "inputParameters": {
      "stage": "required",
      "biomarkers": "required",
      "comorbidities": "recommended",
      "performanceStatus": "required"
    },
    "nccnReferences": [
      "BINV-8"
    ],
    "recommendedActions": [
      "Bottom pathway revised: Adjuvant chemotherapy followed by endocrine therapy ± ovarian suppression/ablation (category 1). Consider adjuvant"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": "0.90",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:30.363Z",
    "updatedAt": "2025-06-28T17:06:30.363Z"
  },
  {
    "id": "6876e3e4-0065-46d8-9cb2-954cf894eb40",
    "moduleType": "general",
    "clinicalScenario": "BINV-8",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "Bottom pathway revised: Adjuvant chemotherapy followed by endocrine therapy ± ovarian suppression/ablation (category 1). Consider adjuvant"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:30.436Z",
    "updatedAt": "2025-06-28T17:06:30.436Z"
  },
  {
    "id": "d93f199a-e87e-4454-9c9e-e33e83701ace",
    "moduleType": "cdu",
    "clinicalScenario": "Systemic therapy selection and administration",
    "inputParameters": {
      "stage": "required",
      "biomarkers": "required",
      "comorbidities": "recommended",
      "performanceStatus": "required"
    },
    "nccnReferences": [
      "BINV-9"
    ],
    "recommendedActions": [
      "pT1c-pT3 pathway revised: Adjuvant chemotherapy with trastuzumab (category 1) (± pertuzumab for pT2-T3)"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": "0.90",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:30.583Z",
    "updatedAt": "2025-06-28T17:06:30.583Z"
  },
  {
    "id": "7de8aeb7-2b61-43ae-b571-ad152c0b45c5",
    "moduleType": "general",
    "clinicalScenario": "BINV-9",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "pT1c-pT3 pathway revised: Adjuvant chemotherapy with trastuzumab (category 1) (± pertuzumab for pT2-T3)"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:30.657Z",
    "updatedAt": "2025-06-28T17:06:30.657Z"
  },
  {
    "id": "5d735b63-d349-47ea-a4df-304ff07f84fa",
    "moduleType": "opd",
    "clinicalScenario": "Initial breast cancer workup and staging",
    "inputParameters": {
      "age": "required",
      "symptoms": "required",
      "familyHistory": "recommended",
      "priorBreastImaging": "recommended"
    },
    "nccnReferences": [
      "BINV-10"
    ],
    "recommendedActions": [
      "Last column, middle pathway revised: Consider adjuvant chemotherapy and adjuvant olaparib if germline BRCA1/2 mutation, see BINV-M for eligibility",
      "Last column, bottom pathway revised: Adjuvant chemotherapy (category 1) and adjuvant olaparib if germline BRCA1/2 mutation, see BINV-M for"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": "0.95",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:30.804Z",
    "updatedAt": "2025-06-28T17:06:30.804Z"
  },
  {
    "id": "25df14a3-9e26-4170-bbe6-926131faf37a",
    "moduleType": "cdu",
    "clinicalScenario": "Systemic therapy selection and administration",
    "inputParameters": {
      "stage": "required",
      "biomarkers": "required",
      "comorbidities": "recommended",
      "performanceStatus": "required"
    },
    "nccnReferences": [
      "BINV-10"
    ],
    "recommendedActions": [
      "Last column, middle pathway revised: Consider adjuvant chemotherapy and adjuvant olaparib if germline BRCA1/2 mutation, see BINV-M for eligibility",
      "Last column, bottom pathway revised: Adjuvant chemotherapy (category 1) and adjuvant olaparib if germline BRCA1/2 mutation, see BINV-M for"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": "0.90",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:30.878Z",
    "updatedAt": "2025-06-28T17:06:30.878Z"
  },
  {
    "id": "afd2ff3e-d57d-4429-834f-28eeccf63cfc",
    "moduleType": "general",
    "clinicalScenario": "BINV-10",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "Last column, middle pathway revised: Consider adjuvant chemotherapy and adjuvant olaparib if germline BRCA1/2 mutation, see BINV-M for eligibility",
      "Last column, bottom pathway revised: Adjuvant chemotherapy (category 1) and adjuvant olaparib if germline BRCA1/2 mutation, see BINV-M for"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:30.952Z",
    "updatedAt": "2025-06-28T17:06:30.952Z"
  },
  {
    "id": "74e7918a-1638-417e-8530-519057f27df2",
    "moduleType": "opd",
    "clinicalScenario": "Initial breast cancer workup and staging",
    "inputParameters": {
      "age": "required",
      "symptoms": "required",
      "familyHistory": "recommended",
      "priorBreastImaging": "recommended"
    },
    "nccnReferences": [
      "BINV-14"
    ],
    "recommendedActions": [
      "Footnote t added: Special Considerations for Breast Cancer in Males (Sex Assigned at Birth) (BINV-J). (Also for BINV-15 and BINV-16)"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.95",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:31.099Z",
    "updatedAt": "2025-06-28T17:06:31.099Z"
  },
  {
    "id": "8bfcc6b8-2603-4329-9695-07c7178b0c96",
    "moduleType": "opd",
    "clinicalScenario": "Initial breast cancer workup and staging",
    "inputParameters": {
      "age": "required",
      "symptoms": "required",
      "familyHistory": "recommended",
      "priorBreastImaging": "recommended"
    },
    "nccnReferences": [
      "BINV-16"
    ],
    "recommendedActions": [
      "Footnote removed: High-risk criteria include stage II–III TNBC. The use of adjuvant pembrolizumab (category 2A) may be individualized."
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.95",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:31.248Z",
    "updatedAt": "2025-06-28T17:06:31.248Z"
  },
  {
    "id": "281ab36b-bac3-46f8-8d1a-b6d7f5720d03",
    "moduleType": "opd",
    "clinicalScenario": "Initial breast cancer workup and staging",
    "inputParameters": {
      "age": "required",
      "symptoms": "required",
      "familyHistory": "recommended",
      "priorBreastImaging": "recommended"
    },
    "nccnReferences": [
      "BINV-17"
    ],
    "recommendedActions": [
      "Endocrine therapy"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.95",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:31.395Z",
    "updatedAt": "2025-06-28T17:06:31.395Z"
  },
  {
    "id": "c8ff5961-c262-4d09-a4de-8ff7de1d6242",
    "moduleType": "opd",
    "clinicalScenario": "Initial breast cancer workup and staging",
    "inputParameters": {
      "age": "required",
      "symptoms": "required",
      "familyHistory": "recommended",
      "priorBreastImaging": "recommended"
    },
    "nccnReferences": [
      "BINV-18"
    ],
    "recommendedActions": [
      "Workup, Imaging for systemic staging",
      "Footnote iii revised: Tumor tissue or plasma-based circulating tumor DNA (ctDNA) assays may be used and each of these have benefits and limitations for diagnosis",
      "Footnote kkk added: In the setting of oligometastatic breast cancer, the currently available data do not support ablative metastasis-directed RT (ie, stereotactic body"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.95",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:31.633Z",
    "updatedAt": "2025-06-28T17:06:31.633Z"
  },
  {
    "id": "da305ff1-810b-4ad8-902a-75cc5fde51f9",
    "moduleType": "general",
    "clinicalScenario": "BINV-18",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "Workup, Imaging for systemic staging",
      "Footnote iii revised: Tumor tissue or plasma-based circulating tumor DNA (ctDNA) assays may be used and each of these have benefits and limitations for diagnosis",
      "Footnote kkk added: In the setting of oligometastatic breast cancer, the currently available data do not support ablative metastasis-directed RT (ie, stereotactic body"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:31.786Z",
    "updatedAt": "2025-06-28T17:06:31.786Z"
  },
  {
    "id": "7c3aef57-0e1a-47c4-b3c7-ef8605b6c2d8",
    "moduleType": "opd",
    "clinicalScenario": "Initial breast cancer workup and staging",
    "inputParameters": {
      "age": "required",
      "symptoms": "required",
      "familyHistory": "recommended",
      "priorBreastImaging": "recommended"
    },
    "nccnReferences": [
      "BINV-19"
    ],
    "recommendedActions": [
      "Column 3",
      "Footnote mmm revised: In patients with a local breast recurrence after BCS who had a prior SLNB, a repeat SLNB may be considered although the accuracy of repeat"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.95",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:31.933Z",
    "updatedAt": "2025-06-28T17:06:31.933Z"
  },
  {
    "id": "45962c69-24e6-4a1c-8b2a-5b0aad9bc77d",
    "moduleType": "general",
    "clinicalScenario": "BINV-19",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "Column 3",
      "Footnote mmm revised: In patients with a local breast recurrence after BCS who had a prior SLNB, a repeat SLNB may be considered although the accuracy of repeat"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:32.007Z",
    "updatedAt": "2025-06-28T17:06:32.007Z"
  },
  {
    "id": "500ca0fe-0f9c-4b91-a4f7-3bee5c28cd8b",
    "moduleType": "general",
    "clinicalScenario": "BINV-22",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "Footnote removed: If progression on initial endocrine therapy, switch to a different endocrine therapy option."
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:32.155Z",
    "updatedAt": "2025-06-28T17:06:32.155Z"
  },
  {
    "id": "92e11f4c-9c21-4086-8610-65a67a199968",
    "moduleType": "cdu",
    "clinicalScenario": "Systemic therapy selection and administration",
    "inputParameters": {
      "stage": "required",
      "biomarkers": "required",
      "comorbidities": "recommended",
      "performanceStatus": "required"
    },
    "nccnReferences": [
      "BINV-25"
    ],
    "recommendedActions": [
      "Top pathway, column 4 revised: Systemic therapy + ± HER2-targeted therapy until progression",
      "Footnote cccc revised: Continue HER2-targeted therapy following progression on first-line HER2-targeted chemotherapy for metastatic breast cancer. The optimal"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.90",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:32.302Z",
    "updatedAt": "2025-06-28T17:06:32.302Z"
  },
  {
    "id": "8dc905b2-b69d-46f8-9f94-4dfa5438f065",
    "moduleType": "general",
    "clinicalScenario": "BINV-25",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "Top pathway, column 4 revised: Systemic therapy + ± HER2-targeted therapy until progression",
      "Footnote cccc revised: Continue HER2-targeted therapy following progression on first-line HER2-targeted chemotherapy for metastatic breast cancer. The optimal"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:32.524Z",
    "updatedAt": "2025-06-28T17:06:32.524Z"
  },
  {
    "id": "719f2ec2-39af-4a34-9031-50d107b1e81b",
    "moduleType": "cdu",
    "clinicalScenario": "Systemic therapy selection and administration",
    "inputParameters": {
      "stage": "required",
      "biomarkers": "required",
      "comorbidities": "recommended",
      "performanceStatus": "required"
    },
    "nccnReferences": [
      "BINV-26"
    ],
    "recommendedActions": [
      "Column 4 revised: Alternate systemic therapy + HER2-targeted therapy until progression"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.90",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:32.669Z",
    "updatedAt": "2025-06-28T17:06:32.669Z"
  },
  {
    "id": "c8918b2d-90e0-47c9-8f68-fbe184f6f3d1",
    "moduleType": "general",
    "clinicalScenario": "BINV-26",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "Column 4 revised: Alternate systemic therapy + HER2-targeted therapy until progression"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:32.891Z",
    "updatedAt": "2025-06-28T17:06:32.891Z"
  },
  {
    "id": "c860c220-5061-4500-950e-69088f31a8f0",
    "moduleType": "general",
    "clinicalScenario": "BINV-28",
    "inputParameters": {
      "patientFactors": "required",
      "clinicalContext": "variable"
    },
    "nccnReferences": [
      "General NCCN"
    ],
    "recommendedActions": [
      "New section: Principles of Survivorship for Those Living with Advanced or Metastatic Breast Cancer",
      "Footnote d revised: The distinction between HER2 IHC 0 with no membrane staining from IHC 0+ with faint, partial membrane staining in ≤10%, 1+, or 2+/ISH negative"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": "0.80",
    "lastReviewed": null,
    "createdAt": "2025-06-28T17:06:33.260Z",
    "updatedAt": "2025-06-28T17:06:33.260Z"
  },
  {
    "id": "b1ee9e7d-2edb-46bb-86a1-47f4b4f714f8",
    "moduleType": "OPD",
    "clinicalScenario": "Ampullary Adenocarcinoma Screening",
    "inputParameters": {
      "symptoms": [
        "Abdominal pain",
        "Jaundice",
        "Weight loss"
      ],
      "cancerType": "Ampullary Adenocarcinoma",
      "riskFactors": [
        "Family history",
        "Hereditary cancer syndromes"
      ]
    },
    "nccnReferences": [
      "AMP-1"
    ],
    "recommendedActions": [
      "Digital rectal examination and inguinal lymph node evaluation",
      "Chest/abdomen/pelvis CT or MRI imaging",
      "Consider FDG-PET/CT for staging",
      "Genetic testing for hereditary cancer syndromes",
      "HIV testing if status unknown"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": null,
    "lastReviewed": null,
    "createdAt": "2025-06-29T00:16:25.128Z",
    "updatedAt": "2025-06-29T00:16:25.128Z"
  },
  {
    "id": "b8eac020-e1f5-4339-835a-633104f7a592",
    "moduleType": "CDU",
    "clinicalScenario": "Ampullary Adenocarcinoma Treatment Protocols",
    "inputParameters": {
      "stage": "Localized",
      "biomarkers": [
        "HER2",
        "MSI-H",
        "dMMR"
      ],
      "performanceStatus": "Good"
    },
    "nccnReferences": [
      "AMP-4"
    ],
    "recommendedActions": [
      "Pancreatoduodenectomy with adjuvant chemoradiation",
      "Perioperative immunotherapy for MSI-H/dMMR tumors",
      "HER2-targeted therapy for HER2+ tumors",
      "Multidisciplinary team consultation"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": null,
    "lastReviewed": null,
    "createdAt": "2025-06-29T00:16:25.212Z",
    "updatedAt": "2025-06-29T00:16:25.212Z"
  },
  {
    "id": "19caaf79-fef7-4fb1-93bd-f03851fcff4d",
    "moduleType": "Inpatient",
    "clinicalScenario": "Postoperative Ampullary Adenocarcinoma Management",
    "inputParameters": {
      "pathology": "R0 resection",
      "complications": "None",
      "surgicalStatus": "Post-pancreatoduodenectomy"
    },
    "nccnReferences": [
      "AMP-5"
    ],
    "recommendedActions": [
      "Adjuvant chemotherapy with or without chemoradiation",
      "Follow GAST-F systemic therapy principles",
      "Regular surveillance imaging",
      "Nutritional support and pancreatic enzyme replacement"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": null,
    "lastReviewed": null,
    "createdAt": "2025-06-29T00:16:25.287Z",
    "updatedAt": "2025-06-29T00:16:25.287Z"
  },
  {
    "id": "6243de95-27b1-4679-ab03-dec7e1f09f84",
    "moduleType": "Palliative",
    "clinicalScenario": "Metastatic Ampullary Adenocarcinoma",
    "inputParameters": {
      "stage": "Metastatic",
      "symptoms": [
        "Pain",
        "Jaundice",
        "Fatigue"
      ],
      "performanceStatus": "ECOG 2"
    },
    "nccnReferences": [
      "AMP-6"
    ],
    "recommendedActions": [
      "Palliative care consultation",
      "Symptom-directed management",
      "Biliary stenting for jaundice",
      "Nutritional support",
      "Psychosocial support"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": null,
    "lastReviewed": null,
    "createdAt": "2025-06-29T00:16:25.362Z",
    "updatedAt": "2025-06-29T00:16:25.362Z"
  },
  {
    "id": "b516b132-df93-4e3e-bd2a-f5850b25853a",
    "moduleType": "Clinical Tools",
    "clinicalScenario": "Ampullary Adenocarcinoma Risk Assessment",
    "inputParameters": {
      "biomarkers": [
        "BRCA1",
        "BRCA2",
        "MLH1",
        "MSH2"
      ],
      "familyHistory": "Positive",
      "geneticTesting": "Required"
    },
    "nccnReferences": [
      "AMP-1"
    ],
    "recommendedActions": [
      "Genetic counseling referral",
      "Comprehensive gene panel testing",
      "Family screening recommendations",
      "Risk-reducing strategies discussion"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": null,
    "lastReviewed": null,
    "createdAt": "2025-06-29T00:16:25.437Z",
    "updatedAt": "2025-06-29T00:16:25.437Z"
  },
  {
    "id": "b49ba27e-d2d8-4307-acac-ece5fa4fc799",
    "moduleType": "OPD",
    "clinicalScenario": "Ampullary Adenocarcinoma Screening",
    "inputParameters": {
      "symptoms": [
        "Abdominal pain",
        "Jaundice",
        "Weight loss"
      ],
      "cancerType": "Ampullary Adenocarcinoma",
      "riskFactors": [
        "Family history",
        "Hereditary cancer syndromes"
      ]
    },
    "nccnReferences": [
      "AMP-1"
    ],
    "recommendedActions": [
      "Digital rectal examination and inguinal lymph node evaluation",
      "Chest/abdomen/pelvis CT or MRI imaging",
      "Consider FDG-PET/CT for staging",
      "Genetic testing for hereditary cancer syndromes",
      "HIV testing if status unknown"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": null,
    "lastReviewed": null,
    "createdAt": "2025-06-29T00:17:04.547Z",
    "updatedAt": "2025-06-29T00:17:04.547Z"
  },
  {
    "id": "a0b3cb77-982d-4013-a56f-2e6e2633ddf5",
    "moduleType": "CDU",
    "clinicalScenario": "Ampullary Adenocarcinoma Treatment Protocols",
    "inputParameters": {
      "stage": "Localized",
      "biomarkers": [
        "HER2",
        "MSI-H",
        "dMMR"
      ],
      "performanceStatus": "Good"
    },
    "nccnReferences": [
      "AMP-4"
    ],
    "recommendedActions": [
      "Pancreatoduodenectomy with adjuvant chemoradiation",
      "Perioperative immunotherapy for MSI-H/dMMR tumors",
      "HER2-targeted therapy for HER2+ tumors",
      "Multidisciplinary team consultation"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": null,
    "lastReviewed": null,
    "createdAt": "2025-06-29T00:17:04.625Z",
    "updatedAt": "2025-06-29T00:17:04.625Z"
  },
  {
    "id": "31b8921b-add9-4200-abd3-83293852f203",
    "moduleType": "Inpatient",
    "clinicalScenario": "Postoperative Ampullary Adenocarcinoma Management",
    "inputParameters": {
      "pathology": "R0 resection",
      "complications": "None",
      "surgicalStatus": "Post-pancreatoduodenectomy"
    },
    "nccnReferences": [
      "AMP-5"
    ],
    "recommendedActions": [
      "Adjuvant chemotherapy with or without chemoradiation",
      "Follow GAST-F systemic therapy principles",
      "Regular surveillance imaging",
      "Nutritional support and pancreatic enzyme replacement"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": null,
    "lastReviewed": null,
    "createdAt": "2025-06-29T00:17:04.701Z",
    "updatedAt": "2025-06-29T00:17:04.701Z"
  },
  {
    "id": "14c5c5d1-70b9-4631-b2e3-14a6ca83f296",
    "moduleType": "Palliative",
    "clinicalScenario": "Metastatic Ampullary Adenocarcinoma",
    "inputParameters": {
      "stage": "Metastatic",
      "symptoms": [
        "Pain",
        "Jaundice",
        "Fatigue"
      ],
      "performanceStatus": "ECOG 2"
    },
    "nccnReferences": [
      "AMP-6"
    ],
    "recommendedActions": [
      "Palliative care consultation",
      "Symptom-directed management",
      "Biliary stenting for jaundice",
      "Nutritional support",
      "Psychosocial support"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": null,
    "lastReviewed": null,
    "createdAt": "2025-06-29T00:17:04.785Z",
    "updatedAt": "2025-06-29T00:17:04.785Z"
  },
  {
    "id": "a68a065a-38a5-4f7c-8642-709064340193",
    "moduleType": "Clinical Tools",
    "clinicalScenario": "Ampullary Adenocarcinoma Risk Assessment",
    "inputParameters": {
      "biomarkers": [
        "BRCA1",
        "BRCA2",
        "MLH1",
        "MSH2"
      ],
      "familyHistory": "Positive",
      "geneticTesting": "Required"
    },
    "nccnReferences": [
      "AMP-1"
    ],
    "recommendedActions": [
      "Genetic counseling referral",
      "Comprehensive gene panel testing",
      "Family screening recommendations",
      "Risk-reducing strategies discussion"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 1",
    "consensusLevel": null,
    "applicabilityScore": null,
    "lastReviewed": null,
    "createdAt": "2025-06-29T00:17:04.862Z",
    "updatedAt": "2025-06-29T00:17:04.862Z"
  },
  {
    "id": "225bf84f-6aef-4c8c-ae33-e3d797b94405",
    "moduleType": "OPD",
    "clinicalScenario": "Bone Cancer Workup and Age-Based Evaluation",
    "inputParameters": {
      "age": "Variable",
      "imaging": "Abnormal x-ray",
      "presentation": "Symptomatic bone lesion"
    },
    "nccnReferences": [
      "BONE-1"
    ],
    "recommendedActions": [
      "Age <40: Refer to orthopedic oncologist immediately",
      "Age ≥40: Workup for bone metastasis first",
      "Multidisciplinary team evaluation",
      "Biopsy at treating institution only",
      "Complete staging workup per NCCN guidelines"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": null,
    "lastReviewed": null,
    "createdAt": "2025-06-29T00:26:38.366Z",
    "updatedAt": "2025-06-29T00:26:38.366Z"
  },
  {
    "id": "b7385616-d867-4b30-a9ab-65e275a62833",
    "moduleType": "CDU",
    "clinicalScenario": "Osteosarcoma Treatment Protocols",
    "inputParameters": {
      "age": "Pediatric/Young Adult",
      "stage": "Localized",
      "resectability": "Resectable"
    },
    "nccnReferences": [
      "OSTEO-1",
      "OSTEO-2"
    ],
    "recommendedActions": [
      "Neoadjuvant chemotherapy (MAP or doxorubicin/cisplatin)",
      "Surgical resection with wide margins",
      "Histologic response assessment",
      "Adjuvant chemotherapy based on response",
      "Fertility consultation consideration"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": null,
    "lastReviewed": null,
    "createdAt": "2025-06-29T00:26:38.442Z",
    "updatedAt": "2025-06-29T00:26:38.442Z"
  },
  {
    "id": "4e8a78d4-f08f-41e8-9c99-43121e8ddb8f",
    "moduleType": "CDU",
    "clinicalScenario": "Ewing Sarcoma Systemic Therapy",
    "inputParameters": {
      "age": "Pediatric/Young Adult",
      "stage": "Localized or Metastatic",
      "cytogenetics": "EWSR1 rearrangement confirmed"
    },
    "nccnReferences": [
      "EW-1",
      "EW-2"
    ],
    "recommendedActions": [
      "Multi-agent chemotherapy (VDC/IE or similar)",
      "Local therapy (surgery and/or radiation)",
      "FDG-PET/CT for staging and response",
      "Consider clinical trial participation",
      "Cytogenetic confirmation essential"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": null,
    "lastReviewed": null,
    "createdAt": "2025-06-29T00:26:38.516Z",
    "updatedAt": "2025-06-29T00:26:38.516Z"
  },
  {
    "id": "dcb5cec4-76e3-4b73-bfae-3d5cbe3935c7",
    "moduleType": "Inpatient",
    "clinicalScenario": "Bone Cancer Postoperative Management",
    "inputParameters": {
      "margins": "Negative",
      "surgery": "Wide resection completed",
      "complications": "Standard postoperative care"
    },
    "nccnReferences": [
      "OSTEO-2",
      "BONE-A"
    ],
    "recommendedActions": [
      "Assess surgical margins and histologic response",
      "Plan adjuvant therapy based on tumor type",
      "Monitor for surgical complications",
      "Physical therapy and rehabilitation",
      "Discharge planning with oncology follow-up"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": null,
    "lastReviewed": null,
    "createdAt": "2025-06-29T00:26:38.589Z",
    "updatedAt": "2025-06-29T00:26:38.589Z"
  },
  {
    "id": "c58ca63a-bde5-4d02-b78d-dd6a6aaf2f2c",
    "moduleType": "Palliative",
    "clinicalScenario": "Metastatic Bone Cancer Symptom Management",
    "inputParameters": {
      "stage": "Metastatic",
      "symptoms": "Pain, functional limitation",
      "performance": "Declining"
    },
    "nccnReferences": [
      "OSTEO-4",
      "CHON-4"
    ],
    "recommendedActions": [
      "Palliative radiation therapy for pain control",
      "Multidisciplinary palliative care consultation",
      "Pain management optimization",
      "Functional assessment and support",
      "Psychosocial support for patient and family"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": null,
    "lastReviewed": null,
    "createdAt": "2025-06-29T00:26:38.662Z",
    "updatedAt": "2025-06-29T00:26:38.662Z"
  },
  {
    "id": "2e0d6bd3-a60d-414e-ab1a-dbc094dc440d",
    "moduleType": "Clinical Tools",
    "clinicalScenario": "Bone Cancer Risk Assessment and Staging",
    "inputParameters": {
      "size": "Variable",
      "location": "Variable",
      "tumorType": "Variable"
    },
    "nccnReferences": [
      "BONE-1",
      "TEAM-1"
    ],
    "recommendedActions": [
      "Complete staging workup per tumor type",
      "Multidisciplinary team evaluation",
      "Risk stratification based on histology",
      "Treatment planning optimization",
      "Prognostic factor assessment"
    ],
    "alternativeOptions": null,
    "riskStratification": null,
    "evidenceStrength": "Category 2A",
    "consensusLevel": null,
    "applicabilityScore": null,
    "lastReviewed": null,
    "createdAt": "2025-06-29T00:26:38.734Z",
    "updatedAt": "2025-06-29T00:26:38.734Z"
  }
]